小细胞肺癌脑转移的防治

doi:10.3760/cma.j.issn.1673-422X.2014.08.010

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (8): 588-592.doi: 10.3760/cma.j.issn.1673-422X.2014.08.010

小细胞肺癌脑转移的防治

高超,于甬华

250062 济南大学山东省医学科学院医学与生命科学学院（高超）；山东省肿瘤医院放疗二病区（高超、于甬华）

收稿日期:2014-02-24 修回日期:2014-03-26 出版日期:2014-08-15 发布日期:2014-08-14
通讯作者: 于甬华，E-mail：sdyonghuayu@163.com E-mail:sdyonghuayu@163.com

Prevention and therapy of small cell lung cancer with brain metastasis

Gao Chao, Yu Yonghua

School of Medicine and Life Sciences, University of Ji′nanShandong Academy of Medical Sciences; Second Department of Radiation Oncology, Shandong Cancer Hospital, Ji′nan 250062, China

Received:2014-02-24 Revised:2014-03-26 Online:2014-08-15 Published:2014-08-14
Contact: Yu Yonghua E-mail:sdyonghuayu@163.com

摘要/Abstract

摘要： 小细胞肺癌脑转移是脑转移性肿瘤中最常见的类型，且预后较差。研究表明，预防性全脑放疗不仅在局限期小细胞肺癌脑转移的预防和诊治中有效，对于广泛期同样有效。另外某些药物如甘露醇、尼莫司汀等同样起到了重要辅助作用，但是在预防和治疗方面还有很多不确定的地方，尚存争议，需要进一步研究。

关键词: 癌, 小细胞, 肺肿瘤, 肿瘤转移, 放射疗法, 药物疗法

Abstract: Small cell lung cancer with brain metastasis is the most common type in brain metastasis tumors with the poor prognosis. Researches show that prophylactic cranial irradiation is not only effective in the prevention and treatment of limited disease brain metastases of small cell lung cancer, but also effective for extensive disease. Moreover, certain medications such as mannitol, nimustine etc also play an important supporting role, but there are many other uncertain parts in terms of prevention and treatment remaining controversial and needing further research.

Key words: Carcinoma, small cell, Lung neoplasms, Neoplasm metastasis, Radiotherapy, Drug therapy

高超,于甬华. 小细胞肺癌脑转移的防治[J]. 国际肿瘤学杂志, 2014, 41(8): 588-592.

Gao Chao, Yu Yonghua. Prevention and therapy of small cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2014, 41(8): 588-592.

参考文献

［1］ Blanchard P, Le Péchoux C. Prophylactic cranial irradiation in lung cancer［J］. Curr Opin Oncol, 2010, 22(2): 94-101. ［2］ Pesce GA, Klingbiel D, Ribi K, et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase Ⅱ trial of the Sweiss Groupfor Clinical Cancer Research (SAKK 70/03)[J]. Eur J Cancer, 2012, 48(3): 377-384. ［3］ Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer［J］. Cancer, 2009, 115(4): 842-850. ［4］胡晓, 陈明. 局限期小细胞肺癌预防性全脑照射：争议与研究进展［J］.中国肺癌杂志, 2013, 16(7): 373-377. ［5］ Tai P, Assouline A, Joseph K, et al. Prophylactic cranial irradiation for patients with limitedstage smallcell lung cancer with response to chemoradiation［J］. Clin Lung Cancer, 2013, 14(1): 40-44. ［6］ Schild SE, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in smallcell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis［J］. Ann Oncol, 2012, 23(11): 2919-2924. ［7］ Giuliani M, Sun A, Bezjak A, et al. Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma［J］. Cancer, 2010, 116(24): 5694-5699. ［8］ Ramlov A, Tietze A, Khalil AA, et al. Prophylactic cranial irradiation in patients with small cell lung cancer. A retrospective study of recurrence, survival and morbidity［J］. Lung Cancer, 2012, 77(3): 561-566. ［9］ Paumier A, Cuenca X, Le Péchoux C. Prophylactic cranial irradiation in lung cancer［J］. Cancer Treat Rev, 2011, 37(4): 261-265. ［10］ Le Péchoux C, Dunant A, Senan S, et al. Standarddose versus higherdose prophylactic cranial irradiation (PCI) in patients with limitedstage smallcell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 9901, EORTC 2200308004, RTOG 0212, and IFCT 9901): a randomised clinical trial［J］. Lancet Oncol, 2009, 10(5): 467-474. ［11］ Slotman B, FaivreFinn C, Kramer G, et al. Prophylactic cranial irradiation in extensive smallcell lung cancer［J］. N Engl J Med, 2007, 357(7): 664-672. ［12］ Ganti AK, West WW, Zhen W. Current concepts in the management of small cell lung cancer［J］. Indian J Med Res, 2013, 137(6): 1043-1051. ［13］ Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive smallcell lung cancer: shortterm healthrelated quality of life and patient reported symptoms: results of an international phase Ⅲ randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. ［J］. J Clin Oncol, 2009, 27(1): 78-84. ［14］ HarfordWright E, Lewis KM, Vink R. Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface［J］. Recent Pat CNS Drug Discov, 2011, 6(1): 31-40. ［15］ Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas［J］. Neurology, 2011, 76(1): 87-93. ［16］郭振勇, 赵伟杰, 刘菲. 炎症和高渗溶液对莫西沙星透过血脑脊液屏障影响的研究及疗效评价［J］. 中国医院用药评价与分析, 2010, 10(9): 822-823. ［17］任成波, 赵丽霞, 赵增虎, 等. 甘露醇在预防小细胞肺癌脑转移中的作用［J］. 现代肿瘤医学, 2012, 20(4): 744-745. ［18］钱皓瑜, 陈卓昌, 郭晓斌, 等. 尼莫司汀预防小细胞肺癌脑转移疗效观察［J］. 中华实用诊断与治疗杂志, 2011, 25(7): 701-702. ［19］ Liu LB, Xue YX, Liu YH. Bradykinin increases the permeability of the bloodtumor barrier by the caveolaemediated transcellular pathway［J］. J Neurooncol, 2010, 99(2): 187-194. ［20］ Qin LJ, Gu YT, Zhang H, et al. Bradykinininduced bloodtumor barrier opening is mediated by tumor necrosis factoralpha［J］. Neurosci Lett, 2009, 450(2): 172-175. ［21］ Ma T, Xue Y. RhoAmediated potential regulation of bloodtumor barrier permeability by bradykinin［J］. J Mol Neurosci, 2010, 42(1): 67-73. ［22］ Li Z, Liu YH, Xue YX, et al. Signal mechanisms underlying lowdose endothelial monocyteactivating polypeptideⅡinduced opening of the bloodtumor barrier［J］. J Mol Neurosci, 2012, 48(1): 291-301. ［23］ Gu YT, Xue YX, Wang YF, et al. Minoxidil sulfate induced the increase in bloodbrain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway［J］. Neuropharmacology, 2013, 75: 407-415.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[5]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[6]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[7]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[8]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[9]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[10]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[11]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[12]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[13]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[14]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[15]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.

小细胞肺癌脑转移的防治

Prevention and therapy of small cell lung cancer with brain metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价